These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35595823)

  • 21. Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
    Han N; Zhou D; Ruan M; Yan M; Zhang C
    Oral Oncol; 2023 Oct; 145():106524. PubMed ID: 37482043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.
    Li D; Yao C; Ding Z; Liu P; Chen X; Liu W; Yi F; Jiang C; Li H; Liu Y; Wu J
    Cancer Med; 2023 Mar; 12(5):5703-5717. PubMed ID: 36217758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes.
    Cui Z; Cao W; Li J; Song X; Mao L; Chen W
    PLoS One; 2013; 8(5):e63887. PubMed ID: 23717505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.
    Starska-Kowarska K
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.
    Luo X; Chen Y; Tang H; Wang H; Jiang E; Shao Z; Liu K; Zhou X; Shang Z
    Cancer Sci; 2022 Jul; 113(7):2232-2245. PubMed ID: 35298069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis.
    Chang YC; Chi LH; Chang WM; Su CY; Lin YF; Chen CL; Chen MH; Chang PM; Wu AT; Hsiao M
    J Hematol Oncol; 2017 Jan; 10(1):11. PubMed ID: 28061796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Payne K; Pugh M; Brooks J; Batis N; Taylor G; Nankivell P; Mehanna H
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Wei F; Fang R; Lyu K; Liao J; Long Y; Yang J; Wen W; Sun W
    Oral Oncol; 2023 Oct; 145():106532. PubMed ID: 37499326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune gene expression in head and neck squamous cell carcinoma patients.
    Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
    Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
    Lakshmanachetty S; Balaiya V; High WA; Koster MI
    Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
    Bhola NE; Njatcha C; Hu L; Lee ED; Shiah JV; Kim MO; Johnson DE; Grandis JR
    Head Neck; 2021 Nov; 43(11):3364-3373. PubMed ID: 34346116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
    Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
    Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.
    Mao L; Fan TF; Wu L; Yu GT; Deng WW; Chen L; Bu LL; Ma SR; Liu B; Bian Y; Kulkarni AB; Zhang WF; Sun ZJ
    J Cell Mol Med; 2017 Sep; 21(9):2199-2210. PubMed ID: 28401653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 40. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
    Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
    Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.